Imipenem cilastatin

Imipenem cilastatin

Combination of
Imipenem	Carbapenem antibiotic
Cilastatin	Dehydropeptidase inhibitor
[[{{{component3}}}]]	? Class
[[{{{component4}}}]]	? Class
[[{{{component5}}}]]	? Class
Clinical data
ATC code	J01DH51 (WHO)
Identifiers
CAS Number	92309-29-0
PubChem CID	11954222
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}

WikiDoc Resources for Imipenem cilastatin
Articles
Most recent articles on Imipenem cilastatin Most cited articles on Imipenem cilastatin Review articles on Imipenem cilastatin Articles on Imipenem cilastatin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Imipenem cilastatin Images of Imipenem cilastatin Photos of Imipenem cilastatin Podcasts & MP3s on Imipenem cilastatin Videos on Imipenem cilastatin
Evidence Based Medicine
Cochrane Collaboration on Imipenem cilastatin Bandolier on Imipenem cilastatin TRIP on Imipenem cilastatin
Clinical Trials
Ongoing Trials on Imipenem cilastatin at Clinical Trials.gov Trial results on Imipenem cilastatin Clinical Trials on Imipenem cilastatin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Imipenem cilastatin NICE Guidance on Imipenem cilastatin NHS PRODIGY Guidance FDA on Imipenem cilastatin CDC on Imipenem cilastatin
Books
Books on Imipenem cilastatin
News
Imipenem cilastatin in the news Be alerted to news on Imipenem cilastatin News trends on Imipenem cilastatin
Commentary
Blogs on Imipenem cilastatin
Definitions
Definitions of Imipenem cilastatin
Patient Resources / Community
Patient resources on Imipenem cilastatin Discussion groups on Imipenem cilastatin Patient Handouts on Imipenem cilastatin Directions to Hospitals Treating Imipenem cilastatin Risk calculators and risk factors for Imipenem cilastatin
Healthcare Provider Resources
Symptoms of Imipenem cilastatin Causes & Risk Factors for Imipenem cilastatin Diagnostic studies for Imipenem cilastatin Treatment of Imipenem cilastatin
Continuing Medical Education (CME)
CME Programs on Imipenem cilastatin
International
Imipenem cilastatin en Espanol Imipenem cilastatin en Francais
Business
Imipenem cilastatin in the Marketplace Patents on Imipenem cilastatin
Experimental / Informatics
List of terms related to Imipenem cilastatin

Imipenem/cilastatin is a broad spectrum beta-lactam antibiotic containing equal quantities of imipenem and cilastatin. It is related to the penicillin/cephalosporin family of antibiotics but is classified as belonging to the carbapenem class. It has the ability to kill a wide variety of bacteria. It works by interfering with their ability to form cell walls, and therefore the bacteria break up and die.

Imipenem, the active antibacterial agent, is rapidly degraded by the renal enzyme dehydropeptidase if administered alone (making it less effective). Cilastatin is a dehydropeptidase inhibitor, with no intrinsic antibacterial activity, and must be co-administered with imipenem to ensure its efficacy. Cilastatin blocks the effects of the renal enzyme. Cilastatin has no antibacterial effects and does not affect the antibacterial activity of the imipenim.

The usual dose for adults is 500 mg every 6 hours. This drug is given by injection or infusion and is generally used to treat severe infections. It may be less likely to cause an allergic reaction in people who have had an allergic reaction to a penicillin in the past.

Imipenem/cilastatin is marketed by Merck & Co. under the trade names Primaxin and Tienam. The combination is also marketed by Ranbaxy Laboratories in India under the brand name Cilanim.

Imipenem/cilastatin is marketed by Highnoon Laboratories Ltd. in Pakistan under the the trade name "Prepenem". Prepenem was launched by Highnoon in May 2007 and was the first generic brand after the research brand Tienam. Prepenem was launched by Kashif Iftikhar, the current Product Manager.

Template:WikiDoc Sources